ReviewFuture microbiology2015
Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection.
Review in Future microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study.BMC infectious diseases · 2017Trial
- Retrospective Study of Epidemiological and Clinical Characteristics of Mpox-HIV Coinfection in Men Who Have Sex with Men in Hangzhou, China.AIDS and behavior · 2026Article
- HIV-1 genetic diversity and pretreatment drug resistance in Xishuangbanna, a China-Myanmar-Laos border region.BMC infectious diseases · 2026Article
- HIVGenoPipe: a nextflow pipeline for the detection of HIV-1 drug resistance using a real-time sample-specific reference sequence.BMC bioinformatics · 2025Article
- Review
- Article
- Cryo-EM structures of wild-type and E138K/M184I mutant HIV-1 RT/DNA complexed with inhibitors doravirine and rilpivirine.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Insights into HIV-1 Reverse Transcriptase (RT) Inhibition and Drug Resistance from Thirty Years of Structural Studies.Viruses · 2022Review
- Research on the Necessity of AIDS Intervention for College Students Based on Cognitive Behavioral Therapy.Current HIV research · 2022Article
- Activity of Selected Nucleoside Analogue ProTides against Zika Virus in Human Neural Stem Cells.Viruses · 2019Article
- Next-generation sequencing of HIV-1 single genome amplicons.Biomolecular detection and quantification · 2019Article
- Focus on recently developed assays for detection of resistance/sensitivity to reverse transcriptase inhibitors.Applied microbiology and biotechnology · 2018Review
- Microwave-Assisted Expeditious Synthesis of 2-Alkyl-2-(Molecules (Basel, Switzerland) · 2018Article
- Antiretroviral resistance in HIV-1 patients at a tertiary medical institute in Saudi Arabia: a retrospective study and analysis.BMC infectious diseases · 2018Article
- Validation and implementation of liquid chromatographic-mass spectrometric (LC-MS) methods for the quantification of tenofovir prodrugs.Journal of pharmaceutical and biomedical analysis · 2018Article
- Article
- Isatin thiazoline hybrids as dual inhibitors of HIV-1 reverse transcriptase.Journal of enzyme inhibition and medicinal chemistry · 2017Article
- Decoding HIV resistance: from genotype to therapy.Future medicinal chemistry · 2017Review
- Nevirapine induced mitochondrial dysfunction in HepG2 cells.Scientific reports · 2017Article
- Discovery, characterization, and lead optimization of 7-azaindole non-nucleoside HIV-1 reverse transcriptase inhibitors.Bioorganic & medicinal chemistry letters · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Inhibitors that target the retroviral enzyme reverse transcriptase (RT) have played an indispensable role in the treatment and prevention of HIV-1 infection. They can be grouped into two distinct therapeutic groups, namely the nucleoside and nucleotide RT inhibitors (NRTIs), and the non-nucleoside RT inhibitors (NNRTIs). NRTIs form the backbones of most first- and second-line antiretroviral therapy (ART) regimens formulated for the treatment of HIV-1 infection. They are also used to prevent mother-to-child transmission, and as pre-exposure prophylaxis in individuals at risk of HIV-1 infection. The NNRTIs nevirapine (NVP), efavirenz and rilpivirine also used to form part of first-line ART regimens, although this is no longer recommended, while etravirine can be used in salvage ART regimens. A single-dose of NVP administered to both mother and child has routinely been used in resource-limited settings to reduce the rate of HIV-1 transmission. Unfortunately, the development of HIV-1 resistance to RT inhibitors can compromise the efficacy of these antiviral drugs in both the treatment and prevention arenas. Here, we provide an up-to-date review on drug-resistance mutations in HIV-1 RT, and discuss their cross-resistance profiles, molecular mechanisms and clinical significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.